HTBX HEAT BIOLOGICS INC

Scorpius Holdings Cancels Planned Reverse Stock Split

Scorpius Holdings Cancels Planned Reverse Stock Split

DURHAM, N.C., Jan. 17, 2025 (GLOBE NEWSWIRE) -- (NYSE American: SCPX) (“Scorpius” or “the Company”), an integrated contract development and manufacturing organization (“CDMO”), today announced that the Company’s planned 1-for-20 reverse stock split (the “Reverse Stock Split”) of its common stock (the “Common Stock”) that was announced yesterday, will not be effectuated.

Scorpius Holdings, Inc.

Scorpius Holdings, Inc. is an integrated contract development and manufacturing organization (CDMO) focused on rapidly advancing biologic programs to the clinic and beyond. Scorpius offers a broad array of analytical testing, process development, and manufacturing services to pharmaceutical and biotech companies at its state-of-the-art facilities in San Antonio, TX. With an experienced team and new, purpose-built U.S. facilities, Scorpius is dedicated to transparent collaboration and flexible, high-quality biologics biomanufacturing. For more information, please visit .

Media and Investor Relations Contact

David Waldman





EN
17/01/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on HEAT BIOLOGICS INC

 PRESS RELEASE

Scorpius Holdings Announces Corporate Update Including Cost Optimizati...

Scorpius Holdings Announces Corporate Update Including Cost Optimization Initiatives, Strategic Corporate Developments, and Potential Opportunities for Expansion into Southeast Asia Operational Realignment Expected to Deliver Over $6 Million in Annual Cost Savings Company Exploring CDMO Expansion Opportunities in Southeast Asia San Antonio, TX , May 05, 2025 (GLOBE NEWSWIRE) -- (OTC: SCPX) (“Scorpius” or “the Company”), an integrated contract development and manufacturing organization ("CDMO”), today provided a corporate update highlighting key strategic initiatives, including cost o...

 PRESS RELEASE

Scorpius Holdings Provides 2024 Year-End Business Update; Implements S...

Scorpius Holdings Provides 2024 Year-End Business Update; Implements Strategic Cost Reductions and Operational Streamlining SAN ANTONIO, April 30, 2025 (GLOBE NEWSWIRE) -- (OTC: SCPX) (“Scorpius” or “the Company”), an integrated contract development and manufacturing organization ("CDMO”), today provided strategic, financial, and operational updates for the year ended December 31, 2024. Jeff Wolf, CEO of Scorpius Holdings, Inc., stated, "The current biotech funding environment has created real headwinds for many of our clients, particularly when it comes to advancing drug development an...

 PRESS RELEASE

Scorpius Holdings Receives NYSE American Notice of Delisting and Repor...

Scorpius Holdings Receives NYSE American Notice of Delisting and Reports Plans to Appeal San Antonio, TX, April 21, 2025 (GLOBE NEWSWIRE) -- (NYSE American: SCPX) (“Scorpius” or “the Company”), an integrated contract development and manufacturing organization (“CDMO”), today reported that it received notice from the NYSE American LLC (“NYSE American” or the “Exchange”) of its determination to commence delisting proceedings of the Company’s common stock from the exchange pursuant to Section 1003(f)(v) of the NYSE American Company Guide due to the low-selling price of the Company’s common ...

 PRESS RELEASE

Scorpius Holdings Engages Alliance Global Partners to Explore Strategi...

Scorpius Holdings Engages Alliance Global Partners to Explore Strategic Alternatives DURHAM, N.C., Feb. 26, 2025 (GLOBE NEWSWIRE) -- (NYSE American: SCPX) (“Scorpius” or “the Company”), an integrated contract development and manufacturing organization ("CDMO"), today announced that it has engaged Alliance Global Partners (“A.G.P.”) to assist in exploring strategic alternatives for the Company. This engagement is part of the Company’s ongoing efforts to maximize shareholder value and evaluate a range of potential strategic opportunities. Scorpius’ leadership remains committed to leveragin...

 PRESS RELEASE

Scorpius Holdings Announces Collaboration with KaloCyte to Advance Man...

Scorpius Holdings Announces Collaboration with KaloCyte to Advance Manufacturing for ErythroMer™ Partnership highlights Scorpius’ expertise in supporting innovative therapeutic programs DURHAM, N.C., Jan. 22, 2025 (GLOBE NEWSWIRE) -- (NYSE American: SCPX) (“Scorpius” or “the Company”), an integrated contract development and manufacturing organization (“CDMO”), today announced its collaboration with KaloCyte, a pioneering pre-clinical company in the field of therapeutic innovation. Under this initial project, Scorpius will utilize its scientific and technical expertise to enhance manufa...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch